Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edward Paule who wrote (6403)	6/2/1998 1:57:00 PM
From: aknahow	Read Replies (3) \| Respond to of 17367

Ed, I think safety is a big issue and even though there have been no problems to date the DSMB would feel remiss not doing a review of the data. It's a statistical review of the data. Even though few additional accruals will probably be made from the end of Sept. thru Dec. if there were safety concerns no one would want even this few placed at risk. However, putting on my own pair of glasses I suppose I can see your point. If the data showed exceptional efficiency the DSMB might recommend the trial be stopped. Taking them off I have trouble seeing how with a relative small number in the total trial can lead to what will be considered statistically significant exceptional efficiency. However, I don't have much doubt that Neuprex will be found to be statistically better, when the trial is completed.